AERIE PHARMACEUTICALS INC Quarterly Debt-to-equity in % from Q2 2014 to Q3 2022

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Aerie Pharmaceuticals Inc quarterly Debt-to-equity history and growth rate from Q2 2014 to Q3 2022.
  • Aerie Pharmaceuticals Inc Debt-to-equity for the quarter ending September 30, 2022 was -454 %, a 71.4% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2022 -454 +1.13K +71.4% Sep 30, 2022
Q2 2022 -538 -4.8K -113% Jun 30, 2022
Q1 2022 -700 -1.53K -185% Mar 31, 2022
Q4 2021 -1.17K -1.59K -379% Dec 31, 2021
Q3 2021 -1.59K -1.85K -702% Sep 30, 2021
Q2 2021 4.26K +4.07K +2126% Jun 30, 2021
Q1 2021 828 +688 +493% Mar 31, 2021
Q4 2020 420 +323 +332% Dec 31, 2020
Q3 2020 264 +203 +335% Sep 30, 2020
Q2 2020 192 +162 +554% Jun 30, 2020
Q1 2020 139 +102 +277% Mar 31, 2020
Q4 2019 97.4 +53.1 +120% Dec 31, 2019
Q3 2019 60.7 -0.12 -0.2% Sep 30, 2019
Q2 2019 29.3 -55.4 -65.4% Jun 30, 2019
Q1 2019 37 -46.6 -55.7% Mar 31, 2019
Q4 2018 44.3 -59.4 -57.3% Dec 31, 2018
Q3 2018 60.8 -46.5 -43.3% Sep 30, 2018
Q2 2018 84.6 -27.5 -24.5% Jun 30, 2018
Q1 2018 83.5 -103 -55.1% Mar 31, 2018
Q4 2017 104 -154 -59.8% Dec 31, 2017
Q3 2017 107 -321 -74.9% Sep 30, 2017
Q2 2017 112 -1.55K -93.3% Jun 30, 2017
Q1 2017 186 -479 -72% Mar 31, 2017
Q4 2016 258 -170 -39.7% Dec 31, 2016
Q3 2016 428 +34 +8.64% Sep 30, 2016
Q2 2016 1.66K +1.3K +360% Jun 30, 2016
Q1 2016 665 +424 +176% Mar 31, 2016
Q4 2015 428 +281 +192% Dec 31, 2015
Q3 2015 394 +330 +517% Sep 30, 2015
Q2 2015 362 +319 +755% Jun 30, 2015
Q1 2015 241 Mar 31, 2015
Q4 2014 146 Dec 31, 2014
Q3 2014 63.8 Sep 30, 2014
Q2 2014 42.3 Jun 30, 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.